|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Feng RM, Zong YN, Cao SM and Xu RH:
Current cancer situation in China: Good or bad news from the 2018
Global Cancer Statistics? Cancer Commun (Lond).
39(22)2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Chen W, Zheng R, Zhang S, Zeng H, Xia C,
Zuo T, Yang Z, Zou X and He J: Cancer incidence and mortality in
China, 2013. Cancer Lett. 401:63–71. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Gatzka MV: Targeted tumor therapy
remixed-an update on the use of small-molecule drugs in combination
therapies. Cancers (Basel). 10(155)2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Avery JC and Hoffmann PR: Selenium,
selenoproteins, and immunity. Nutrients. 10(1203)2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Huang Z, Rose AH and Hoffmann PR: The role
of selenium in inflammation and immunity: From molecular mechanisms
to therapeutic opportunities. Antioxid Redox Sign. 16:705–743.
2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Fairweather-Tait SJ, Bao Y, Broadley MR,
Collings R, Ford D, Hesketh JE and Hurst R: Selenium in human
health and disease. Antioxid Redox Sign. 14:1337–1383.
2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Rayman MP: Selenium and human health.
Lancet. 379:1256–1268. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Short SP and Williams CS: Selenoproteins
in tumorigenesis and cancer progression. Adv Cancer Res. 136:49–83.
2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Méplan C: Association of single nucleotide
polymorphisms in selenoprotein genes with cancer risk. Methods Mol
Biol. 1661:313–324. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hatfield DL, Carlson BA, Tsuji PA, Tobe R
and Gladyshev VN: Selenium and cancer. In: Molecular, Genetic, and
Nutritional Aspects of Major and Trace Minerals. Collins J (ed).
Academic Press, New York, NY, pp463-473, 2017.
|
|
14
|
Meyer HA, Endermann T, Stephan C, Stoedter
M, Behrends T, Wolff I, Jung K and Schomburg L: Selenoprotein P
status correlates to cancer-specific mortality in renal cancer
patients. PLoS One. 7(e46644)2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lincoln DT, Ali EME, Tonissen KF and
Clarke FM: The thioredoxin-thioredoxin reductase system:
Over-expression in human cancer. Anticancer Res. 23:2425–2433.
2003.PubMed/NCBI
|
|
16
|
Jabłońska E and Reszka E: Selenium and
epigenetics in cancer: Focus on DNA methylation. Adv Cancer Res.
136:193–234. 2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Liu CJ, Hu FF, Xia MX, Han L, Zhang Q and
Guo AY: GSCALite: A web server for gene set cancer analysis.
Bioinformatics. 34:3771–3772. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Győrffy B, Surowiak P, Budczies J and
Lánczky A: Online survival analysis software to assess the
prognostic value of biomarkers using transcriptomic data in
non-small-cell lung cancer. PLoS One. 8(e82241)2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Menyhárt O, Nagy Á and Győrffy B:
Determining consistent prognostic biomarkers of overall survival
and vascular invasion in hepatocellular carcinoma. R Soc Open Sci.
5(181006)2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yagublu V, Arthur JR, Babayeva SN, Nicol
F, Post S and Keese M: Expression of selenium-containing proteins
in human colon carcinoma tissue. Anticancer Res. 31:2693–2698.
2011.PubMed/NCBI
|
|
21
|
Berggren M, Gallegos A, Gasdaska JR,
Gasdaska PY, Warneke J and Powis G: Thioredoxin and thioredoxin
reductase gene expression in human tumors and cell lines, and the
effects of serum stimulation and hypoxia. Anticancer Res.
16:3459–3466. 1996.PubMed/NCBI
|
|
22
|
Murawaki Y, Tsuchiya H, Kanbe T, Harada K,
Yashima K, Nozaka K, Tanida O, Kohno M, Mukoyama T, Nishimuki E, et
al: Aberrant expression of selenoproteins in the progression of
colorectal cancer. Cancer Lett. 259:218–230. 2008.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Peters KM, Carlson BA, Gladyshev VN and
Tsuji PA: Selenoproteins in colon cancer. Free Radic Biol Med.
127:14–25. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Méplan C and Hesketh J: The influence of
selenium and selenoprotein gene variants on colorectal cancer risk.
Mutagenesis. 27:177–186. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Méplan C, Hughes DJ, Pardini B, Naccarati
A, Soucek P, Vodickova L, Hlavatá I, Vrána D, Vodicka P and Hesketh
JE: Genetic variants in selenoprotein genes increase risk of
colorectal cancer. Carcinogenesis. 31:1074–1079. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wang W, Green M, Choi JE, Gijón M, Kennedy
PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, et al: CD8(+) T
cells regulate tumour ferroptosis during cancer immunotherapy.
Nature. 569:270–274. 2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hassannia B, Vandenabeele P and Berghe TV:
Targeting ferroptosis to iron out cancer. Cancer Cell. 35:830–849.
2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lei Z, Tian D, Zhang C, Zhao S and Su M:
Clinicopathological and prognostic significance of GPX2 protein
expression in esophageal squamous cell carcinoma. BMC Cancer.
16(410)2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Silvers AL, Lin L, Bass AJ, Chen G, Wang
Z, Thomas DG, Lin J, Giordano TJ, Orringer MB, Beer DG and Chang
AC: Decreased selenium-binding protein 1 in esophageal
adenocarcinoma results from posttranscriptional and epigenetic
regulation and affects chemosensitivity. Clin Cancer Res.
16:2009–2021. 2010.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Takata Y, Kristal AR, Santella RM, King
IB, Duggan DJ, Lampe JW, Rayman MP, Blount PL, Reid BJ, Vaughan TL
and Peters U: Selenium, selenoenzymes, oxidative stress and risk of
neoplastic progression from Barrett's esophagus: Results from
biomarkers and genetic variants. PLoS One. 7(e38612)2012.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Steevens J, Schouten LJ, Driessen ALC,
Huysentruyt CJ, Keulemans YC, Goldbohm RA and van den Brandt PA:
Toenail selenium status and the risk of Barrett's esophagus: The
Netherlands Cohort Study. Cancer Causes Control. 21:2259–2268.
2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Seale LA: Selenocysteine β-Lyase:
Biochemistry, regulation and physiological role of the
selenocysteine decomposition enzyme. Antioxidants (Basel).
8(357)2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Li CL, Nan KJ, Tian T, Sui CG and Liu YF:
Selenoprotein P mRNA expression in human hepatic tissues. World J
Gastroenterol. 13:2363–2368. 2007.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zheng Y, Liu Y, Zhao S, Zheng Z, Shen C,
An L and Yuan Y: Large-scale analysis reveals a novel risk score to
predict overall survival in hepatocellular carcinoma. Cancer Manag
Res. 10:6079–6096. 2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Lee D, Xu IMJ, Chiu DKC, Leibold J, Tse
AP, Bao MH, Yuen VW, Chan CY, Lai RK, Chin DW, et al: Induction of
oxidative stress through inhibition of thioredoxin reductase 1 is
an effective therapeutic approach for hepatocellular carcinoma.
Hepatology. 69:1768–1786. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Tuo L, Xiang J, Pan X, Gao Q, Zhang G,
Yang Y, Liang L, Xia J, Wang K and Tang N: PCK1 downregulation
promotes TXNRD1 expression and hepatoma cell growth via the
Nrf2/Keap1 pathway. Front Oncol. 8(611)2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Gao Q, Zhang G, Zheng Y, Yang Y, Chen C,
Xia J, Liang L, Lei C, Hu Y, Cai X, et al: SLC27A5 deficiency
activates NRF2/TXNRD1 pathway by increased lipid peroxidation in
HCC. Cell Death Differ. 27:1086–1104. 2020.PubMed/NCBI
|
|
38
|
Fu B, Meng W, Zeng X, Zhao H, Liu W and
Zhang T: TXNRD1 is an unfavorable prognostic factor for patients
with hepatocellular carcinoma. Biomed Res Int.
2017(4698167)2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Shang N, Wang X, Shu Q, Wang H and Zhao L:
The functions of selenium and selenoproteins relating to the liver
diseases. J Nanosci Nanotechnol. 19:1875–1888. 2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Tarek M, Louka ML, Khairy E, Ali-Labib R,
Zakaria Zaky D and Montasser IF: Role of microRNA-7 and
selenoprotein P in hepatocellular carcinoma. Tumor Biol.
39(1010428317698372)2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Hughes DJ, Duarte-Salles T, Hybsier S,
Trichopoulou A, Stepien M, Aleksandrova K, Overvad K, Tjønneland A,
Olsen A, Affret A, et al: Prediagnostic selenium status and
hepatobiliary cancer risk in the European Prospective Investigation
into Cancer and Nutrition cohort. Am J Clin Nutr. 104:406–414.
2016.PubMed/NCBI View Article : Google Scholar
|
|
42
|
DI Stasio M, Volpe MG, Colonna G, Nazzaro
M, Polimeno M, Scala S, Castello G and Costantini S: A possible
predictive marker of progression for hepatocellular carcinoma.
Oncol Lett. 2:1247–1251. 2011.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Jia Y, Dai J, Zhang LL and Xia H:
Biological functions of selenium-binding protein 1 and its
relationship with diseases. Prog Biochem Biophys. 46:128–137.
2019.
|
|
44
|
Guariniello S, Colonna G, Raucci R,
Costantini M, Di Bernardo G, Bergantino F, Castello G and
Costantini S: Structure-function relationship and evolutionary
history of the human selenoprotein M (SelM) found over-expressed in
hepatocellular carcinoma. Biochim Biophys Acta. 1844:447–456.
2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Na J, Jung J, Bang J, Lu Q, Carlson BA,
Guo X, Gladyshev VN, Kim J, Hatfield DL and Lee BJ: Selenophosphate
synthetase 1 and its role in redox homeostasis, defense and
proliferation. Free Radic Biol Med. 127:190–197. 2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Jaworska K, Gupta S, Durda K, Muszyńska M,
Sukiennicki G, Jaworowska E, Grodzki T, Sulikowski M, Waloszczyk P,
Wójcik J, et al: A low selenium level is associated with lung and
laryngeal cancers. PLoS One. 8(e59051)2013.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Epplein M, Burk RF, Cai Q, Hargreaves MK
and Blot WJ: A prospective study of plasma Selenoprotein P and lung
cancer risk among low-income adults. Cancer Epidemiol Biomarkers
Prev. 23:1238–1244. 2014.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Gresner P, Gromadzinska J, Jablonska E,
Kaczmarski J and Wasowicz W: Expression of selenoprotein-coding
genes SEPP1, SEP15 and hGPX1 in non-small cell lung cancer. Lung
Cancer. 65:34–40. 2009.PubMed/NCBI View Article : Google Scholar
|
|
49
|
An BC, Choi YD, Oh IJ, Kim JH, Park JI and
Lee SW: GPx3-mediated redox signaling arrests the cell cycle and
acts as a tumor suppressor in lung cancer cell lines. PLoS One.
13(e0204170)2018.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Oh IJ, Kim HE, Song SY, Na KJ, Kim KS, Kim
YC and Lee SW: Diagnostic value of serum glutathione peroxidase 3
levels in patients with lung cancer. Thorac Cancer. 5:425–430.
2014.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Choi JY, An BC, Jung IJ, Kim JH and Lee
SW: MiR-921 directly downregulates GPx3 in A549 lung cancer cells.
Gene. 700:163–167. 2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Chen G, Wang H, Miller CT, Thomas DG,
Gharib TG, Misek DE, Giordano TJ, Orringer MB, Hanash SM and Beer
DG: Reduced selenium-binding protein 1 expression is associated
with poor outcome in lung adenocarcinomas. J Pathol. 202:321–329.
2004.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Marciel MP, Khadka VS, Deng Y, Kilicaslan
P, Pham A, Bertino P, Lee K, Chen S, Glibetic N, Hoffmann FW, et
al: Selenoprotein K deficiency inhibits melanoma by reducing
calcium flux required for tumor growth and metastasis. Oncotarget.
9:13407–3422. 2018.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Jeong D, Kim TS, Chung YW, Lee BJ and Kim
IY: Selenoprotein W is a glutathione-dependent antioxidant in vivo.
FEBS Lett. 517:225–228. 2002.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Xu X, Huang L, Chan CH, Yu T, Miao R and
Liu C: Assessing the clinical utility of genomic expression data
across human cancers. Oncotarget. 7:45926–45936. 2016.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Marciel MP and Hoffmann PR: Molecular
mechanisms by which Selenoprotein K regulates immunity and cancer.
Biol Trace Elem Res. 192:60–68. 2019.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Min SY, Kim HS, Jung EJ, Do Jee C and Kim
WH: Prognostic significance of glutathione peroxidase 1 (GPX1)
down-regulation and correlation with aberrant promoter methylation
in human gastric cancer. Anticancer Res. 32:3169–3175.
2012.PubMed/NCBI
|
|
58
|
Peng DF, Hu TL, Schneider BG, Chen Z, Xu
ZK and El-Rifai W: Silencing of glutathione peroxidase 3 through
DNA hypermethylation is associated with lymph node metastasis in
gastric carcinomas. PLoS One. 7(e46214)2012.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Lan X, Xing J, Gao H, Li S, Quan L, Jiang
Y, Ding S and Xue Y: Decreased expression of selenoproteins as a
poor prognosticator of gastric cancer in humans. Biol Trace Elem
Res. 178:22–28. 2017.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Zhang J, Dong W and Lin J: Reduced
selenium-binding protein 1 is associated with poor survival rate in
gastric carcinoma. Med Oncol. 28:481–487. 2011.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Wang Q, Gong L, Dong R, Qiao Q, He XL, Chu
YK, Du XL, Yang Y, Zang L, Nan J, et al: Tissue microarray
assessment of selenoprotein P expression in gastric adenocarcinoma.
J Int Med Res. 37:169–174. 2009.PubMed/NCBI View Article : Google Scholar
|
